Research analysts covering Quantum Biopharma.
Recent press releases and 8-K filings for QNTM.
Quantum BioPharma Completes Dosing in Lucid-MS Toxicity Studies
QNTM
New Projects/Investments
- Quantum BioPharma Ltd. announced the completion of oral dosing for its drug candidate, Lucid-21-302 (Lucid-MS), in 180-day toxicity and toxicokinetic studies.
- These completed studies are critical components for the Investigational New Drug (IND) application with the US FDA.
- The studies will also support the design of a Phase 2 trial for Lucid-MS, which is intended for the treatment of multiple sclerosis (MS).
- Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of MS.
Dec 23, 2025, 1:00 PM
Quantum BioPharma Ltd. announces US At-The-Market Offering
QNTM
- Quantum BioPharma Ltd. entered into an at-the-market (ATM) offering agreement with Rodman & Renshaw LLC on December 22, 2025.
- Under this agreement, the company may offer and sell Class B Subordinate Voting Shares with an aggregate offering price of up to US$17,243,174.
- Rodman & Renshaw LLC will act as the sales agent, receiving a cash commission of up to 3.0% of the gross proceeds from any sales.
- The net proceeds from the ATM Offering are intended for general corporate purposes and working capital.
Dec 22, 2025, 9:23 PM
Quantum BioPharma Shareholder Files Class Action Lawsuit Against Banks
QNTM
Legal Proceedings
- A class action lawsuit has been filed against Canadian banks CIBC and RBC alleging illegal stock market manipulation of Quantum BioPharma Ltd. (QNTM) shares.
- The alleged manipulation occurred between January 6, 2021, and October 15, 2025, reportedly causing significant and material harm to shareholders who sold securities during this period.
- Quantum BioPharma intends to seek appointment as a lead plaintiff in this class action to assist in protecting its shareholders.
Dec 22, 2025, 12:00 PM
Quantum BioPharma Shareholder Files Class Action Lawsuit
QNTM
Legal Proceedings
- A class action lawsuit has been filed by Quantum BioPharma shareholder Paul Durkacz.
- The lawsuit alleges that investors in Quantum BioPharma were victims of stock manipulation between January 6, 2021, and October 15, 2025, causing harm to shareholders who sold securities.
- Quantum BioPharma intends to seek appointment as a lead plaintiff in this class action to assist in protecting its shareholders.
Dec 19, 2025, 9:52 PM
Quantum BioPharma's Stock Manipulation Lawsuit Featured in W5 Series
QNTM
Legal Proceedings
- Quantum BioPharma Ltd. announced that CTV News' W5 aired the final segment of a three-part series detailing the company's USD $700 million stock market manipulation lawsuit.
- The lawsuit alleges "stock spoofing," an illegal market manipulation tactic, against CIBC and RBC, two of Canada's largest banks.
- The company is offering up to USD $7 million for information that tangibly contributes to the final judgment or binding settlement of ongoing or future litigation concerning the manipulation of its stock.
Dec 1, 2025, 12:00 PM
Quantum BioPharma's Stock Manipulation Lawsuit Featured on W5
QNTM
Legal Proceedings
- Quantum BioPharma Ltd. announced that CTV News' W5 aired Part 2 of a three-part investigative series on alleged stock market manipulation of the company.
- The series highlights Quantum BioPharma's USD $700 million lawsuit against CIBC and RBC, alleging "stock spoofing," an illegal market manipulation tactic.
- Quantum BioPharma claims that Canadian exchange trading data indicates massive stock spoofing, with at least 16 million illegal and fictitious orders originating from Canadian bank platforms.
Nov 28, 2025, 1:25 PM
Quantum BioPharma's USD $700 Million Lawsuit Against Major Banks to be Featured in Investigative News Series
QNTM
Legal Proceedings
- Quantum BioPharma Ltd. announced on November 26, 2025, that CTV News' W5 will air a three-part investigative series focusing on the company's USD $700 million lawsuit.
- The lawsuit alleges stock market manipulation, specifically "stock spoofing," against CIBC and RBC, two of Canada's largest banks.
- Quantum BioPharma's CEO, Zeeshan Saeed, commented that the series aims to highlight the issue of stock spoofing to prevent other companies and their shareholders from experiencing similar market manipulation.
Nov 26, 2025, 2:30 PM
Quantum BioPharma's $700 Million Lawsuit Subject of Investigative News Series
QNTM
Legal Proceedings
- Quantum BioPharma Ltd. announced on November 25, 2025, that CTV News' flagship investigative program W5 will air a three-part series about the company's allegations of stock market manipulation.
- The series focuses on "stock spoofing," an illegal market manipulation tactic, and the basis of Quantum BioPharma's USD $700 million lawsuit against two major Canadian banks, CIBC and RBC.
- The lawsuit alleges that this market manipulation nearly derailed the company's multiple sclerosis research.
- As of September 30, 2025, Quantum BioPharma retains 19.86% ownership of Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity.
Nov 25, 2025, 9:00 PM
Quantum BioPharma Reports Strong Q3 2025 Results and Extends Cash Runway
QNTM
Earnings
Guidance Update
Dividends
- Quantum BioPharma reported strong financial and operational results for the third quarter ending September 30, 2025, maintaining a "no going concern" status and extending its cash runway beyond March 2027.
- The company significantly strengthened its financial position in Q3 2025 compared to Q2 2025, with a 275% increase in shareholder equity to US$7.5 million and a 50% decrease in total liabilities to US$6.6 million, primarily due to the elimination of convertible debentures.
- Year-to-date, Quantum BioPharma realized US$572,000 in gains from its digital asset portfolio.
- Operational progress includes advancing clinical trials for its multiple sclerosis drug, Lucid-21-302, and its licensee, Unbuzzd Wellness Inc., launching a $5.0 million USD capital raise for growth and a possible IPO, which will not dilute Quantum BioPharma's equity.
- Subsequent to Q3 2025, a Special Dividend consisting of contingent value rights was distributed to shareholders, with a record date of October 27, 2025.
Nov 7, 2025, 12:00 PM
Quantum Biopharma Ltd. Reports Q3 2025 Financial Results
QNTM
Earnings
Legal Proceedings
New Projects/Investments
- Quantum Biopharma Ltd. reported a net loss of $23,253,808 for the nine months ended September 30, 2025, compared to a net loss of $9,459,251 for the same period in 2024.
- Cash and cash equivalents significantly decreased by 93% to $445,944 as of September 30, 2025, from $5,995,872 at December 31, 2024, driven by operating outflows of $7.93 million and investing outflows of $2.30 million.
- The company's digital assets increased by 505% to $5,207,249 as of September 30, 2025, from $861,230 at December 31, 2024, due to an expansion of cryptocurrency holdings.
- Total operating expenses rose to $12,928,989 for the nine months ended September 30, 2025, up from $9,895,032 in the prior year period.
- An investigation into possible naked short selling and market manipulation of the Company’s securities is ongoing.
Nov 6, 2025, 9:29 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more